PTC Therapeutics, Inc. research snapshot
PTCT AI stock analysis as of the August 3, 2026 data cutoff reads PTC Therapeutics as a commercial-stage rare disease biopharmaceutical whose Sephience (sepiapterin) launch is driving record revenue, while the stock trades well below its July peak after a sharp post-earnings selloff. The stock closed at $68.01 on July 31, 2026, down 9.94% on heavy volume the day after Q2 results that beat consensus on revenue and EPS and raised 2026 product revenue guidance to $850 million to $950 million. Market capitalization was about $5.67 billion, computed as $68.01 times the 83,327,286 shares outstanding reported in the Q2 2026 Form 10-Q and cross-validated against StockAnalysis.com. The Q2 2026 report, released July 30, 2026, delivered record total revenue of $361 million, product revenue of $238.8 million up more than 100% year over year, Sephience net product revenue of $151.3 million up 21% sequentially with 1,647 commercial patients globally, a $50 million Novartis milestone as the INVEST-HD Phase 3 study started enrollment, and GAAP net income of $83.5 million. Management raised full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion and product revenue guidance to $850 million to $950 million, and said the company could reach cash flow breakeven in 2026. The stock hit a 52-week high of $90.87 on July 9, 2026, pulled back into the report, then fell 9.94% on July 31 despite the beat and the guidance raise, a sell-the-news reaction after a large run that left the shares below all key moving averages with 14-day RSI near 27.7. This is informational research and not investment advice.
Current price
$68.01
Market cap
$5.67 billion
AI score
63 / 100
Rating
Improving commercial execution with high volatility
Trend status
Post-earnings breakdown below all key moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | PTC discovers and commercializes oral small-molecule and gene therapies for rare disorders. Sephience is now the growth engine, with record Q2 total revenue of $361 million and product revenue up more than 100% year over year. | Medium-high |
| Moat | The moat comes from orphan drug exclusivity, a validated splicing platform, gene therapy manufacturing and regulatory barriers, and a global commercial infrastructure in about 50 countries, partly offset by DMD generic erosion and PKU competition. | Medium |
| Management | CEO Matthew B. Klein, who succeeded founder Stuart Peltz, led a Q2 beat, a product revenue guidance raise, and a disciplined refinancing of the 2026 convertible notes at a 0% coupon with a 40% conversion premium. | Medium-high |
| Financial trend | Q2 2026 GAAP net income was $83.5 million versus a net loss of $64.8 million a year earlier, TTM revenue was about $1.01 billion, and the company raised 2026 product revenue guidance to $850 million to $950 million while targeting cash flow breakeven in 2026. | Medium-high |
| Valuation | At about 5.6x TTM sales, a forward PE near 45x to 51x, and negative book value, the stock prices in a successful Sephience ramp and a turn to profitability. The recent selloff reduced but did not remove the premium. | Low-medium |
| Technical trend | PTCT closed at $68.01 on July 31, 2026, below its 5-, 20-, 50-, 100-, and 200-day moving averages, with 14-day RSI near 27.7, a bearish directional setup, and Barchart overall opinion at 8% Sell. | Medium-high |
| Risk level | Key risks are Sephience launch deceleration, votoplam and vatiquinone regulatory outcomes, DMD franchise generic erosion, dilution from the $550 million convertible issuance, a $2.32 billion royalty purchase liability, negative book value, and high short interest. | Medium-high |
| AI confidence | High for descriptive facts and cross-checked math that matched across StockAnalysis.com, SEC EDGAR XBRL, the Q2 2026 earnings release, and the Q2 2026 Form 10-Q. Lower for forward return estimates because Sephience trajectory and regulatory timing are uncertain. | High data confidence |
| Investment certainty | Low-medium certainty. The page gives a research framework and scenario ranges, not a buy or sell instruction. | Low-medium |
PTCT AI stock forecast
The PTCT AI stock forecast uses scenario ranges around the $68.01 July 31, 2026 close. The bullish case assumes the Sephience launch keeps compounding, votoplam gains an accelerated approval path, and cash flow breakeven turns into sustained profitability. The base case assumes steady Sephience growth with slower international contributions and the Phase 3 INVEST-HD study as the approval base case. The bearish case assumes Sephience growth decelerates, a votoplam or vatiquinone setback, or a de-rating toward and below the Goldman Sachs $70 target.
$95 to $120
More likely if Sephience sustains double-digit sequential growth, international markets ramp through 2026 into 2027, votoplam secures an FDA accelerated path on the PIVOT-HD 24-month data, cash flow breakeven arrives in 2026, and GAAP profitability becomes durable.
$65 to $85
More likely if Sephience grows steadily but international reimbursement and HTA processes take until 2027, votoplam approval stays on the Phase 3 INVEST-HD path, and the stock stabilizes in a range while the company approaches cash flow breakeven.
$40 to $55
More likely if Sephience sequential growth slows sharply, votoplam faces clinical or regulatory delay, the vatiquinone NDA resubmission disappoints, dilution from the convertible issuance weighs on shares, or the royalty purchase liability creates cash constraints.
PTCT AI technical analysis
PTCT AI technical analysis is bearish over the short term as of the August 3, 2026 data cutoff. The stock closed at $68.01 on July 31, 2026, below its 5-, 20-, 50-, 100-, and 200-day moving averages, with 14-day RSI near 27.7, a bearish directional setup where the negative directional index of 34.22 sits well above the positive reading of 11.38, and Barchart overall opinion at 8% Sell. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $68.01 | StockAnalysis.com real-time quote at the July 31, 2026 close; market cap math uses the 83,327,286 shares outstanding from the Q2 2026 Form 10-Q. |
| Near resistance | $72.96 to $77.92 | Barchart lists first resistance at $72.96 and second resistance at $77.92, just below the 5-day moving average near $73.84 and the 20-day moving average near $79.62. |
| 52-week high | $90.87 | Reached on July 9, 2026. A return to this level would require a full repair of the downtrend that followed. |
| Near support | $63.81 to $59.61 | Barchart lists first support at $63.81 and second support at $59.61, the zones to watch on further downside. |
| Lower support | $54.66 | Barchart third support point. A close below $59.61 would open the path toward this level. |
| 5-day moving average | $73.84 | Barchart reported the 5-day average near $73.84, above the July 31 close, confirming immediate downside momentum. |
| 20-day moving average | $79.62 | Barchart reported the 20-day average near $79.62, well above price after the sharp selloff. |
| 50-day moving average | $77.14 | Barchart and StockAnalysis.com both reported the 50-day average near $77.14, now a resistance zone. |
| 200-day moving average | $73.11 | Barchart and StockAnalysis.com both reported the 200-day trend line near $73.11, and the close below it broke the longer-term uptrend. |
| Momentum | RSI near 28, oversold | 14-day RSI was near 27.66 to 27.67, oversold, which can precede a bounce but can also persist during breakdowns. |
| Volume | 4.33 million shares on July 31 | Volume was about 4.33 million shares versus a 20-day average near 1.5 million, confirming institutional selling during the post-earnings drop. |
| Volatility | Elevated near 45% to 49% | Barchart reported 14-day historical volatility near 44.9% and 20-day near 48.8%, so position sizing should account for larger swings around clinical and regulatory events. |
| Invalidation | Close below $63.81, recovery above $73.84 | A close below the first support near $63.81 would extend the downside toward $59.61, while a reclaim of the 5-day average near $73.84 would signal the first sign of stabilization. |
PTCT AI trading strategy
The PTCT AI trading strategy is a rules-based research framework for trading and watching a post-earnings breakdown in a high-growth biotech. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level.
With PTCT below all key moving averages, watch for rallies to fail in the $72.96 to $77.92 resistance zone and for volume to confirm any further decline through the $63.81 support.
A close back above the 20-day moving average near $79.62 would invalidate the bearish breakdown setup. Biotech gaps on clinical news require wider stops.
If PTCT stabilizes with RSI near 28 and reclaims the 5-day average near $73.84 on above-average volume, a short-term bounce toward the $77.92 to $79.62 zone becomes a watch area rather than a conviction long.
Oversold readings can stay oversold in downtrends. Require a confirmed reclaim of the 5-day average and do not average down without a maximum loss rule.
Track Sephience weekly demand and patient adds, Q3 sequential product revenue growth, international and HTA milestones, votoplam FDA engagement timing, vatiquinone PROVE-FA initiation, the trajectory against the $850 million to $950 million product revenue guidance, and the pace toward cash flow breakeven.
Reduce exposure if product revenue guidance is cut, Sephience sequential growth turns negative, dilution accelerates, or the Royalty Pharma liability structure changes.
Investment research summary
PTC discovers and commercializes oral small-molecule and gene therapies for rare disorders, with Sephience now the growth engine alongside Translarna, Emflaza, Upstaza and Kebilidi, and Evrysdi royalties from Roche.
The moat is built on orphan drug exclusivity, a validated RNA splicing platform, gene therapy manufacturing and regulatory barriers, and a global commercial infrastructure, though the DMD franchise faces generic erosion and Sephience faces PKU competition.
The thesis fails if Sephience sequential growth stalls, votoplam misses on the approval path, the vatiquinone resubmission fails, DMD franchise erosion outpaces Sephience growth, dilution from the 2031 convertible notes weighs on value, or the royalty sale liability constrains the balance sheet.
CEO Matthew B. Klein, who succeeded founder Stuart Peltz, led a Q2 beat, a product revenue guidance raise, and a disciplined refinancing of the 2026 converts at a 0% coupon with a 40% premium, with CFO Pierre Gravier and CBO Eric Pauwels running the Q2 call.
Rare disease genetics, RNA splicing, and gene therapy remain structurally favored, but pricing and reimbursement pressure, HTA timing, and PKU competition shape the international ramp for Sephience.
At about 5.6x TTM sales, a premium forward multiple, and negative book value, the stock prices in a successful Sephience ramp and near-term profitability. The recent selloff reduced but did not eliminate the premium.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PTCT price | $68.01 at the July 31, 2026 close, down 9.94%, with an after-hours print of $69.24 | StockAnalysis.com real-time quote and price history | August 3, 2026 |
| Market capitalization | $5.67 billion, computed as $68.01 x 83,327,286 shares outstanding from the Q2 2026 Form 10-Q; StockAnalysis.com reports $5.68 billion | StockAnalysis.com statistics and Q2 2026 Form 10-Q | August 3, 2026 |
| Q2 2026 total revenue | $361 million total revenue, including $238.8 million product revenue up more than 100% year over year and $309.9 million product plus royalty revenue | PTC Q2 2026 earnings release and Q2 2026 Form 10-Q | July 30, 2026 |
| Q2 2026 net income | $83.5 million GAAP net income, diluted EPS of $0.92 versus consensus of $0.34, after a net loss of $64.8 million in Q2 2025 | PTC Q2 2026 earnings release and Q2 2026 Form 10-Q | July 30, 2026 |
| Sephience Q2 2026 revenue | $151.3 million net product revenue, up 21% sequentially, with 1,647 commercial patients on therapy globally as of June 30, 2026; the earnings call transcript cites $161 million | PTC Q2 2026 earnings release (primary) and Q2 2026 earnings call transcript | July 30, 2026 |
| 2026 financial guidance | Total revenue raised to $1.18 billion to $1.28 billion, product revenue raised to $850 million to $950 million from $750 million to $850 million, GAAP R&D and SG&A of $775 million to $815 million, non-GAAP of $680 million to $720 million | PTC Q2 2026 earnings release | July 30, 2026 |
| TTM revenue | $1.009 billion TTM as of June 30, 2026, down 42.8% because the one-time $998 million Novartis collaboration revenue fell out of the trailing window; FY2025 revenue was $1.731 billion | StockAnalysis.com financials and FY2025 10-K | August 3, 2026 |
| Cash and marketable securities | $2.229 billion as of June 30, 2026, composed of $1.050 billion cash and equivalents plus $1.179 billion marketable securities, matching SEC EDGAR XBRL (1049887000 and 1179195000) | Q2 2026 Form 10-Q and SEC EDGAR XBRL company-concept JSON | August 3, 2026 |
| Long-term debt | $535.5 million noncurrent plus $55.5 million current as of June 30, 2026, matching SEC EDGAR XBRL; the June 2026 issuance was $550 million of 0% convertible notes due 2031 at a roughly 40% conversion premium | Q2 2026 Form 10-Q and SEC EDGAR XBRL company-concept JSON | August 3, 2026 |
| Royalty purchase liability | $2,321.4 million liability for sale of future royalties as of June 30, 2026, composed of $314.2 million current and $2,007.2 million noncurrent, under the Royalty Pharma agreement that provided $2.1 billion of funding | Q2 2026 Form 10-Q | August 3, 2026 |
| Book value | Stockholders deficit of negative $165.4 million, book value per share of about negative $1.93 to negative $1.98, matching SEC EDGAR XBRL (-165363000) | Q2 2026 Form 10-Q, SEC EDGAR XBRL, and StockAnalysis.com | August 3, 2026 |
| Valuation ratios | PS ratio 5.63x TTM sales, forward PS 4.71x, forward PE 44.75x on the statistics page and about 51.5x on the FY2026 non-GAAP EPS estimate of $1.32, EV/EBITDA 35.74x | StockAnalysis.com statistics and forecast | August 3, 2026 |
| Analyst consensus | Buy with an average target of $97.86 across 14 analysts, median $98, low $70 (Goldman Sachs), high $130 (Cantor Fitzgerald) | StockAnalysis.com forecast | July 31, 2026 |
| Analyst rating mix, July 2026 | 7 Strong Buy, 4 Buy, 2 Hold, 0 Sell, and 1 Strong Sell out of 14 analysts, with Goldman Sachs maintaining a Sell rating at a $70 target on July 31, 2026 | StockAnalysis.com forecast recommendation trends | July 31, 2026 |
| Recent analyst target updates | Cantor Fitzgerald maintained $130 on July 31, Morgan Stanley raised $93 to $104 on July 31, BofA raised $95 to $96 on July 31, Wells Fargo raised $93 to $106, RBC Capital maintained $85 Hold, and Goldman Sachs maintained $70 Sell | StockAnalysis.com forecast and news feed | July 31, 2026 |
| FY2026 and FY2027 consensus estimates | FY2026 revenue estimate of $1.18 billion with non-GAAP EPS of $1.32, and FY2027 revenue estimate of $1.34 billion with EPS of $2.74 | StockAnalysis.com forecast financial forecast | July 31, 2026 |
| Short interest | 9.83 million shares short, 11.78% of shares outstanding, 13.35% of float, 3.61 days to cover, down from 17.32 million shares the previous month | StockAnalysis.com statistics short selling | August 3, 2026 |
| Insider ownership | 2.43% held by insiders | StockAnalysis.com statistics | August 3, 2026 |
| Cash flow | TTM operating cash flow of negative $30.5 million and free cash flow of negative $39.8 million, while H1 2026 operating cash flow was positive $70.1 million per the Q2 2026 Form 10-Q | StockAnalysis.com cash flow statement and Q2 2026 Form 10-Q | August 3, 2026 |
| votoplam Huntington program | PIVOT-HD 24-month data showed dose-dependent slowing on the cUHDRS scale including 52% average slowing in the 10 mg Stage 2 cohort; the Novartis INVEST-HD Phase 3 is enrolling about 770 early symptomatic patients; a $50 million milestone was triggered in Q2 2026; FDA engagement is planned for 2H 2026 | PTC Q2 2026 earnings release and Q2 2026 earnings call | July 30, 2026 |
| vatiquinone Friedreich ataxia program | The PROVE-FA open-label study with a matched natural history control is expected to initiate in Q3 2026 to support NDA resubmission, enrolling about 120 patients ages 7 to 21 with a primary endpoint of change in mFARS at month 24 | PTC Q2 2026 earnings call | July 30, 2026 |
| Pipeline programs | PTC303, an MSH3 splicing program targeting Huntington disease and myotonic dystrophy, targeting the clinic in 2027; PTC612, an oral NLRP3 inhibitor, with Phase 1 initiated in Q2 2026; PTC844, a next-generation DHODH inhibitor, with a Phase 2a study expected in Q3 2026 | PTC Q2 2026 earnings call | July 30, 2026 |
| Convertible refinancing | In June 2026, PTC issued $550 million of senior convertible notes due 2031 at a 0% coupon and a conversion price about 40% above the stock close at deal pricing, and repurchased the majority of its 1.5% notes due September 2026 | PTC Q2 2026 earnings release and earnings call | July 30, 2026 |
| 52-week range and performance | 52-week range of $43.18 to $90.87, up 33.51% over the trailing 52 weeks, beta 0.54 | StockAnalysis.com quote and statistics | August 3, 2026 |
| Technical snapshot | 5-day SMA near $73.84, 20-day SMA near $79.62, 50-day SMA near $77.14, 100-day SMA near $72.94, 200-day SMA near $73.11, 14-day RSI near 27.66, 14-day ADX near 19.38 with negative DI of 34.22 above positive DI of 11.38, 14-day historical volatility near 44.9% | Barchart technical analysis | July 31, 2026 |
| Barchart opinion | Overall 8% Sell across 13 indicators with Trend Seeker at Sell and long-term indicators at 100% Sell; the snapshot was 40% Buy yesterday, 48% Buy last week, and 88% Buy last month | Barchart opinion | July 31, 2026 |
| July 31, 2026 volume | 4.33 million shares traded on July 31, 2026, versus a 20-day average near 1.5 million shares | StockAnalysis.com price history | July 31, 2026 |
| FY2025 results | FY2025 revenue of $1.731 billion up 114.5%, including $998 million of Novartis collaboration and license revenue, with FY2025 net income of $682.6 million | StockAnalysis.com financials | August 3, 2026 |
This PTCT AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, clinical data, regulatory decisions, or market moves. Biopharmaceutical investments carry elevated risk from trial outcomes, regulatory actions, and commercialization uncertainty.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
